NCT03689712 2023-10-24
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
Galera Therapeutics, Inc.
Phase 3 Completed
Clinical Trials
9 trialsNCT03237325 2022-11-08
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Soligenix
Phase 3 Completed
NCT00131638 2016-12-16
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Amgen
Phase 3 Completed
NCT00101582 2016-09-27
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Swedish Orphan Biovitrum
Phase 3 Completed
NCT00434161 2015-03-30
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Swedish Orphan Biovitrum
Phase 3 Completed
NCT00574860 2013-09-20
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Endo Pharmaceuticals
Phase 3 Terminated
NCT00041665 2013-05-08
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
Amgen
Phase 3 Completed
NCT00051441 2011-05-19
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3 Completed
NCT00790322 2010-02-19
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
Biotec Pharmacon ASA
Phase 3 Completed